Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tapentadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tapentadol SCHEMBL29447436 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL3841350 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL146800 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL1425181 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL116924 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267561 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL147058 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16266162 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267909 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL29611116 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133971-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2019-05-09 | — | — | US | claimed |
| US-10206890-B2 | Pharmaceutical combination | GRUENENTHAL GMBH (DE) | 2019-02-19 | — | — | US | claimed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | claimed |
| US-20160361276-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-12-15 | — | — | US | claimed |
| US-20160128952-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-05-12 | — | — | US | claimed |
| EP-2992877-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2016-03-09 | — | — | EP | claimed |
| US-20160045458-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2016-02-18 | — | — | US | claimed |
| EP-2582366-B1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2015-10-28 | — | — | EP | claimed |
| EP-2808319-A1 | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex | Arevipharma GmbH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-20140309311-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2014-10-16 | — | — | US | claimed |
| EP-2012764-B1 | PHARMACEUTICAL COMBINATION COMPRISING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PARACETAMOL | GRUENENTHAL GMBH (DE) | 2011-01-12 | — | — | EP | claimed |
| US-20100190752-A1 | tapentadol and antiepileptic such as gabapentin; synergistic pain relief | GRUENENTHAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| WO-2010025931-A2 | PHARMACEUTICAL COMBINATION | Grünenthal GmbH (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20100063148-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2010-03-11 | — | — | US | claimed |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | GRUENENTHAL GMBH (DE) | 2009-04-16 | — | — | US | claimed |
| EP-2012763-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| EP-2012764-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PARACETAMOL | Grünenthal GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007128412-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- (3-DIMETHYLAMIN0-1-ETHYL-2-METHYL-PR0PYL) -PHENOL AND AN NSAID | Grünenthal GmbH (DE) | 2007-11-15 | — | — | WO | claimed |
| WO-2007128413-A1 | PHARMACEUTICAL COMBINATION COMPRISING 3- ( 3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND PARACETAMOL | Grünenthal GmbH (DE) | 2007-11-15 | — | — | WO | claimed |
| US-20070254960-A1 | PHARMACEUTICAL COMBINATION | GRUENENTHAL GMBH (DE) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190752-A1 | tapentadol and antiepileptic such as gabapentin; synergistic pain relief | GAP43, OPRL1, OPRK1 | OPRM1 23/4885SLC6A2 232/4885SLC22A1 2884/4885 |
| US-20100063148-A1 | Pharmaceutical Combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 616/4885SLC22A1 3549/4885 |
| US-20160361276-A1 | Pharmaceutical Combination | MC2R, PTGER2, PTGER1 | OPRM1 21/4885SLC6A2 743/4885SLC22A1 2078/4885 |
| US-10206890-B2 | Pharmaceutical combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 667/4885SLC22A1 3627/4885 |
| US-20160045458-A1 | Pharmaceutical Combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 667/4885SLC22A1 3627/4885 |
| US-20190133971-A1 | Pharmaceutical Combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 616/4885SLC22A1 3549/4885 |
| US-20070254960-A1 | PHARMACEUTICAL COMBINATION | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885SLC6A2 1348/4885SLC22A1 2635/4885 |
| US-20140309311-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | OPRM1 9/4885SLC6A2 629/4885SLC22A1 3310/4885 |
| US-20090099138-A1 | NSAIDs and tapentadol; synergistic pain relief | PTGS1, OPRL1, PTGES3 | OPRM1 29/4885SLC6A2 96/4885SLC22A1 1301/4885 |
| US-20160128952-A1 | Pharmaceutical Combination | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885SLC6A2 1348/4885SLC22A1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.